Fertility

Overview

Fertility-related peptide therapy targets both male (spermatogenesis, HPG axis, testosterone) and female (folliculogenesis, HPG axis, oocyte quality) reproductive health. Peptides offer more physiological support of the reproductive axis compared to exogenous hormone replacement, which can suppress endogenous function. This category requires close collaboration with a reproductive endocrinologist or fertility specialist.

Recommended Peptides

Kisspeptin-10 – upstream HPG axis activator; triggers GnRH release which drives LH and FSH; studied in IVF protocols for triggering ovulation; improves sperm quality and testosterone in men; naturalizes hormonal signaling
Gonadorelin – synthetic GnRH; used in fertility protocols for follicle stimulation and in men to maintain testicular function and spermatogenesis during or after TRT
Epitalon – protects oocyte DNA integrity; shown to reduce aneuploidy in aging oocyte preparations; may extend reproductive lifespan by preserving ovarian reserve and reducing oxidative damage
Oxytocin – involved in uterine function, embryo implantation, and pair bonding; intranasal use in fertility context is exploratory

Protocols

Sexual Health Protocol

Related Conditions

Research Summary

Kisspeptin receptor agonist MVT-602 demonstrated therapeutic potential for IVF triggering in women with PCOS and hypothalamic amenorrhea (PMID-33196464). GnRH agonists (goserelin, leuprolide) are standard of care for ovarian protection during chemotherapy, reducing premature ovarian insufficiency from 30.9% to 14.1% in a meta-analysis of 873 patients (PMID-29718793). HCG remains widely used for ovulation induction and luteal support.

#condition #reproductive